Entire cohort (n = 74) | Suspected or confirmed COVID-19 cohort (n = 14) | |
---|---|---|
1. Mean age (years) | 23.5 ± 16.1 | 17.6 ± 16.1 |
2. Pediatric MMA | 52.7% | 78.6% |
3. Adult MMA | 47.3% | 21.4% |
4. Male:Female | 1:1.24 | 1:1 |
5. Area of residence | ||
Rural | 64.9% | 71.4% |
Urban | 35.1% | 28.6% |
6. Duration of disease (months) | 41.4 ± 31.5 | 36.3 ± 12.9 |
7. “MMA” type | ||
TIA | 2.7% | 7.1% |
Frequent TIA | 16.2% | 35.7% |
Cerebral infarction | 62.2% | 57.1% |
Intracerebral hemorrhage | 8.1% | 0% |
Headache | 5.4% | 0% |
Epilepsy | 5.4% | 0% |
Asymptomatic | 0% | 0% |
Others | 0% | 0% |
8. Previously documented radiological lesion in brain | ||
Infarct | 85.1% | 78.6% |
Hemorrhage | 6.8% | 0% |
No acute lesion | 8.1% | 21.4% |
9. Suzuki staging in the last documented in angiography | ||
Stage I | 0% | 0% |
Stage II | 9.5% | 7.1% |
Stage III | 29.7% | 28.6% |
Stage IV | 37.8% | 50.0% |
Stage V | 21.6% | 14.2% |
Stage VI | 1.4% | 0% |
10. Time since last follow-up (months) | 9.2 ± 1.7 | 9.6 ± 1.6 |
11. Compliance to prescribed medications | ||
Yes | 90.5% | 92.9% |
No | 9.5% | 7.1% |
12. Neurological symptoms (worsening or new onset) | ||
Yes | 16.2% | 64.3% |
No | 83.8% | 35.7% |